COMMUNIQUÉS West-GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

01/05/2025 - 13:00

WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

01/05/2025 - 13:00

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. [...]

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

01/05/2025 - 13:00

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is [...]

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

01/05/2025 - 13:00

Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize [...]

Microbix Presenting at the 2025 Bloom Burton Conference

01/05/2025 - 13:00

MISSISSAUGA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending and [...]

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

01/05/2025 - 13:00

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft [...]

Ligand to Participate in May Investor Conferences

01/05/2025 - 13:00

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. [...]

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

01/05/2025 - 13:00

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]

Roquette finalise l’acquisition d’IFF Pharma Solutions

01/05/2025 - 08:00

Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la [...]

Roquette Completes the Acquisition of IFF Pharma Solutions

01/05/2025 - 08:00

Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the [...]

Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs

01/05/2025 - 09:00

Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio , a biopharmaceutical company [...]

Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results

01/05/2025 - 06:16

Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 [...]

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

01/05/2025 - 07:00

May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]

Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations

01/05/2025 - 01:05

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s [...]

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

01/05/2025 - 01:12

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA- [...]

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

01/05/2025 - 01:35

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read [...]

SurgiBox Announces Strategic Partnership with BestBrick Medical in Taiwan

01/05/2025 - 02:23

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- SurgiBox, Inc., a pioneering medical technology company dedicated to bringing safe surgery to every patient, today announced a strategic partnership with BestBrick [...]

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

01/05/2025 - 03:30

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today [...]

FORM 8.1(a) & (b) - Mural Oncology plc

30/04/2025 - 21:07

Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE [...]